Despite Impending Challenges, Myriad Offers Rosy Projections at Investor Conference

Although the company is embroiled in a high-profile patent lawsuit involving its flagship BRACAnalysis test, and the FDA's plan to regulate laboratory-developed tests may impact all of its marketed products, Myriad officials maintain a positive outlook.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.